Table 1.

Phase III trials in a metastatic setting

Study	Arms	Patients	Overall response rate (%)	P value	Median progression-free survival (months)	HR (P value)	Overall survival (months)	HR (P value)
AVF2119g	Capecitabine + placebo	230	9.1	0.001	4.2	0.98 (0.857)	14.5	Not reported
	Capecitabine + bevacizumab	232	19.8		4.89		15.1
E2100	Paclitaxel	326	22.2	<0.0001	5.8	0.483 (<0.0001)	25.2	0.88 (0.16)
	Paclitaxel + bevacizumab	347	48.9		11.3		26.7
AVADO	Docetaxel + placebo	241	46.4	Placebo vs. bev7.5: 0.07	8.1	Placebo vs. bev7.5: 0.8 (0.045)	31.9	Placebo vs. bev7.5: 1.05 (0.72)
	Docetaxel + bevacizumab (7.5 mg/kg)	248	55.2		9.0		30.8
	Docetaxel + bevacizumab (15 mg/kg)	247	64.1	Placebo vs. bev15: <0.001	10.0	Placebo vs. bev15: 0.67 (<0.001)	30.2	Placebo vs. bev15: 1.03 (0.85)
RIBBON-1	Capecitabine + placebo	206	23.6	0.0097	5.7	0.69 (<0.001)	21.2	0.85 (0.27)
	Capecitabine + bevacizumab	409	35.4		8.6		29.0
	Anthracycline/taxane + placebo	207	37.9	0.0054	8.0	0.64 (<0.001)	23.8	1.03 (0.83)
	Anthracycline/taxane + bevacizumab	415	51.3		9.2		25.2
RIBBON-2	Taxane or gemcitabine or capecitabine or vinorelbine (chemo) + placebo	225	29.6	0.0193	5.1	0.78 (0.0072)	16.4	0.90 (0.37)
	Chemo + bevacizumab	459	39.5		7.2		18.0